<DOC>
	<DOCNO>NCT01754961</DOCNO>
	<brief_summary>Chronic liver disease associate inflammation . The investigator postulate Vitamin D may modulate inflammation . Thus investigator study effect Vitamin D replacement patient Hepatitis C infection Vitamin D deficiency .</brief_summary>
	<brief_title>Effects Vitamin D Inflammation Liver Disease</brief_title>
	<detailed_description>Vitamin D appear critical signal molecule macrophage need activation differentiation monocytes/macrophages . From Preliminary Studies ( VA Merit Review Grant ) , propose Vitamin D deficiency may alter 'pro-inflammatory ' ( 'classically activate ' ) M1 macrophage , characterize ] high expression NOS2 , TNF-a , IL-1 , IL-6 , IL-8 , TGF-a , CXCL10 , CCL19 ; ii ] minimal expression arginase 1 mannose R. The clinical relevance finding suggest presence activate M1 macrophage liver biopsy patient severe drug-induced liver injury ( unpublished observation ) . Prospective vitamin D supplementation study appropriate endpoint need define role vitamin D inflammation patient chronic liver disease .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Men woman age 18 old Total 25OH Vit D &lt; 25 ng/mL Infection HCV genotype 1 ( subject infect multiple genotype eligible ) . Plasma HCV RNA concentration &gt; 100,000 IU/mL . HCVinfected subject na√Øve treatment : subject either never treat HCV infection previously receive HCV treatment end &gt; 3 month prior enrollment ( include , IFNAlpha without ribavirin , antiHCV antiviral medication ) . Women pregnant breastfeeding . Patients Sarcoidosis , Histoplasmosis , Lymphoma , Primary Hyperparathyroidism Idiophatic Hypercalcemia . Liver Cirrhosis . Known active gastrointestinal disease could interfere absorption test article . Laboratory determination screen follow : Hemoglobin &lt; 10 g/dL . Serum creatinine within normal limit . However , subject may enrol CockroftGault glomerular filtration rate ( GFR ) &gt; 50 mL/minute . Unstable hypertension , cardiac disease type 2 diabetes require change treatment medication 4 week prior screen screen period . Use investigational drug within 4 week screen visit screen period . Use systemic immunosuppressant ( include systemic , oral , intravenous corticosteroid ) immunomodulating agent within 4 week screen visit screen period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>